Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The
discovery of amphotericin B and its therapeutic uses is considered one of the most important …

There is a real consensus that new antibiotics are urgently needed and are the best chance
for combating antibiotic resistance. The phylum Actinobacteria is one of the main producers …

The development of antimicrobial drug resistance among pathogenic bacteria and fungi is
one of the most significant health issues of the 21st century. Recently, advances in …

All serious fungal infections need appropriate antifungal therapy for successful patient
outcome. Only a few classes of antifungal drugs are available, so the emergence of …

Highlights•Our limited arsenal of antifungals is threatened by drug-resistant fungal
pathogens.•Inherent resistance is when all strains of a species show antifungal …

The high clinical mortality and economic burden posed by invasive fungal infections (IFIs),
along with significant agricultural crop loss caused by various fungal species, has resulted in …

We reviewed the licensed antifungal drugs and summarized their mechanisms of action,
pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1 …

Candida spp. infections are a major cause of morbidity and mortality in critically ill patients.
Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …